Study of Obesity Control by Astragalus and Notoginseng Extrats

Obesity Clinical Trial

Official title:

Study of Obesity Control by Astragalus and Notoginseng Extrats

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03654391
• Other study ID #: CS16098
• Status: Completed
• Phase: N/A
• Start date: October 2016
• Est. completion date: October 2017

Study information

• Verified date: December 2019
• Source: Chung Shan Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The effects of the Astragalus and Notoginseng extrats on obesity control was demonstrated in a randomized double-blind, and crossover human trial.

Description:

Obesity refers to the body due to physiological or biochemical function of the change caused by excessive accumulation of body fat, resulting in weight gain. Hence, the aim of this study was to evaluate the effects of the Astragalus and Notoginseng extrats on obesity control by a randomized double-blind and crossover human trial. Subjects with simple obesity (body mass index (BMI) ≥ 27 or body fat ≥ 30%) ingested 5 extrats (n = 19) capsules or placebo (n = 19) perday for 12 weeks of a stage. Anthropometric measurements (body weight, body fat, blood pressure) and blood biochemical markers including fasting blood glucose (FBG), albumin, total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, creatinine (Cr), blood urea nitrogen (BUN), AST, ALT were examined every six weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: October 2017
• Est. primary completion date: August 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• Body mass index (BMI) = 27 or body fat = 30%;

• No history of serious diseases associated with heart, liver, kidney, endocrine systems or other organs;

• No drugs consumption.

Exclusion Criteria:

• BMI >35;

• Alcoholic;

• US-controlled diabetics;

• Stoke in past one year;

• High blood pressure;

• Mental diseases or melancholia;

• Pregency or breast-feeding a child.

Related Conditions & MeSH terms

• Obesity

Intervention

Dietary Supplement:
• InnoSlim
Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
• Placebo
Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Chung Shan Medical University

References & Publications (3)

Chang TC, Huang SF, Yang TC, Chan FN, Lin HC, Chang WL. Effect of ginsenosides on glucose uptake in human Caco-2 cells is mediated through altered Na+/glucose cotransporter 1 expression. J Agric Food Chem. 2007 Mar 7;55(5):1993-8. Epub 2007 Feb 2. — View Citation

Chang W.L. et al. The inhibitory effect of ginse¬noside Rg1 on glucose and lipid production in human HepG2 cells. Adaptive Medicine. 2013, 5(4), 181-188.

Wang CW, Su SC, Huang SF, Huang YC, Chan FN, Kuo YH, Hung MW, Lin HC, Chang WL, Chang TC. An Essential Role of cAMP Response Element Binding Protein in Ginsenoside Rg1-Mediated Inhibition of Na+/Glucose Cotransporter 1 Gene Expression. Mol Pharmacol. 2015 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The changes of body weight and BMI of the subjects.	values change of body weight and BMI between before to after 12 weeks	12 weeks
Secondary	The changes of triglyceride (TG) of the subjects	values change of triglyceride (TG) between before to after 12 weeks	12 weeks